DPP-4阻害薬のすべて

出版社： 先端医学社
著者：
発行日： 2010-06-25
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784884076245
電子書籍版： 2010-06-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

4,730 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,365 円(税込)

購入する

商品紹介

GIP、GLP-1の基礎、さらにDPP-4の基礎とDPP-4阻害薬の糖尿病治療薬としての現状と展望について、わが国を代表するインクレチン研究の専門家による最新の動向と解説。

目次

  • DPP-4阻害薬のすべて

    ―目次―

    Part 1　インクレチンを知る
    　インクレチンの概念と研究の歴史

    Part 2　インクレチンの基礎をみる
    　1．GIPの基礎
    　2．GLP-1の基礎
    　3．その他のインクレチン

    Part 3　DPP-4の基礎をみる
    　DPP-4の基礎

    Part 4　DPP-4阻害薬の基礎をみる
    　1．DPP-4阻害薬の基礎薬理
    　2．DPP-4阻害薬とインスリン／グルカゴン分泌
    　3．DPP-4阻害薬のその他の作用

    Part 5　DPP-4阻害薬の臨床データをみる
    　1．DPP-4阻害薬の臨床薬理
    　2．DPP-4阻害薬の臨床成績
    　
    Part 6　糖尿病治療の問題点と
    　　　　　インクレイチン・DPP-4への期待を探る
    　1．現在の2型糖尿病治療の問題点
    　2．2型糖尿病とインクレチン作用

    Part 7　DPP-4阻害薬の臨床的意義と将来展望を探る
    　1．DPP-4阻害薬の登場で日本の糖尿病治療はこう変わる
    　2．DPP-4阻害薬と他の糖尿病治療薬との違い
    　3．日本人の糖尿病治療におけるDPP-4阻害薬の位置づけ
    　4．DPP-4阻害薬とβ細胞量増加
    　5．QOLからみたDPP-4阻害薬の意義

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 インクレチンを知る

P.21 掲載の参考文献
1) Bayliss WM, Starling EH : The mechanism of pancreatic secretion. J Physiol 28 : 325-353, 1902
PubMed
2) Moore B : On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1 : 28-38, 1906
 
3) Zunz E, La Barre J : Contributions a l'etude des variations physiologiques de la secretion interne du pancreas relations entre les secretions externe et interne du pancreas. Arch Int Physiol Biochim 31 : 20-44, 1929
 
4) Yalow RS, Berson SA : Immunoassay of endogenous plasma insulin in man. J Clin Invest 39 : 1157-1175, 1960
 
5) Elrick H, Stimmler L, Hlad CJ Jr et al : Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 : 1076-1082, 1964
PubMed
6) McIntyre N, Holdsworth CD, Turner DS : New interpretation of oral glucose tolerance. Lancet ii : 20-21, 1964
 
7) Dupre J, Ross SA, Watson D et al : Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37 : 826-828, 1973
 
8) Taminato T, Seino Y, Goto Y et al : Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat. Diabetes 26 : 480-484, 1977
PubMed
9) Seino Y, Fukushima M, Yabe D : GIP and GLP-1, two incretin hormones : Similarities and differences. J Diabetes Invest 1 : 8-23, 2010
 
10) Holst JJ : The physiology of glucagon-like peptide 1. Physiol Rev 87 : 1409-1439, 2007
PubMed
11) Bell GI, Santerre RF, Mullenbach GT : Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 : 716-718, 1983
PubMed
12) Schmidt WE, Siegel EG, Creutzfeldt W : Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28 : 704-707, 1985
PubMed
13) Kreymann B, Williams G, Ghatei MA et al : Glucagon-like peptide-1 7-36 : a physiological incretin in man. Lancet ii : 1300-1304, 1987
 
14) Drucker DJ : The biology of incretin hormones. Cell Metab 3 : 153-165, 2006
PubMed
15) Deacon CF, Holst JJ : Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 23 : 425-432, 2009
PubMed
16) Takemura J, Seino Y, Tsuda K et al : Hypersecretion of gastric inhibitory polypeptide induced by glucose ingestion in diabetes mellitus. Endocrinol Jpn 28 : 17-21, 1981
PubMed
17) Yabe D, Kuroe A, Lee S et al : Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese : Comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 1 : 56-59, 2010
 
18) Takemura J, Seino Y, Yamamura T et al : The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis. J Clin Endocrinol Metab 54 : 909-913, 1982
 
19) Narita T, Katsuura Y, Sato T et al : Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 26 : 187-188, 2009
PubMed
20) Nauck M, Stockmann F, Ebert R et al : Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 : 46-52, 1986
PubMed
21) Ross SA, Brown JC, Dupre J : Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26 : 525-529, 1977
PubMed
22) Vollmer K, Holst JJ, Baller B et al : Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57 : 678-687, 2008
PubMed
23) Nauck MA, Heimesaat MM, Orskov C et al : Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 : 301-307, 1993
 
24) Zander M, Madsbad S, Madsen JL et al : Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes : a parallel-group study. Lancet 359 : 824-830, 2002
 
25) Amori RE, Lau J, Pittas AG : Efficacy and safety of incretin therapy in type 2 diabetes : systematic review and meta-analysis. JAMA 298 : 194-206, 2007
PubMed
26) FDA : Sitagliptin (marketed as Januvia and Janumet) -acute pancreatitis. [Posted 9/25/2009]
 
27) FDA : Information for Healthcare Professionals : Exenatide (marketed as Byetta). [Update 8/18/2008]
 
28) Noel RA, Braun DK, Patterson RE et al : Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes : a retrospective cohort study. Diabetes Care 32 : 834-838, 2009
PubMed
29) Dore DD, Seeger JD, Arnold Chan K : Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25 : 1019-1027, 2009
 
30) Gorrell MD : Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108 : 277-292, 2005
PubMed
31) Kikuchi M, Abe N, Kato M et al : Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83 : 233-240, 2009
PubMed
32) Nonaka K, Kakikawa T, Sato A et al : Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79 : 291-298, 2008
PubMed
33) Seino Y, Rasmussen MF, Zdravkovic M et al : Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain : a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81 : 161-168, 2008
PubMed

Part 2 インクレチンの基礎をみる

P.31 掲載の参考文献
1) Brown JC : A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. CanJ Biochem 49 : 255-261, 1971
PubMed
2) Brown JC, Dryburgh JR : A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 49 : 867-872, 1971
PubMed
3) Inagaki N, Seino Y, Takeda J et al : Gastric inhibitory polypeptide : structure and chromosomal localization of the human gene. Mol Endocrinol 3 : 1014-1021, 1989
PubMed
4) Takeda J, Seino Y, Tanaka K et al : Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 84 : 7005-7008, 1987
PubMed
5) 間中英夫, 深瀬憲雄, 高橋秀夫 : 糖尿病記録号, 佐々木英夫編, 医学図書出版, 東京, 1991, p317
 
6) Takemura J, Seino Y, Yamamura T et al : The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis. J Clin Endocrinol Metab 54 : 909-913, 1982
 
7) Usdin TB, Mezey E, Button DC et al : Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133 : 2861-2870, 1993
PubMed
8) Yasuda K, Inagaki N, Yamada Y et al : Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells : its structure and functional properties. Biochem Biophys Res Commun 205 : 1556-1562, 1994
PubMed
9) Yamada Y, Hayami T, Nakamura K et al : Human gastric inhibitory polypeptide receptor : cloning of the gene (GIPR) and cDNA. Genomics 29 : 773-776, 1995
PubMed
10) Miyawaki K, Yamada Y, Yano H et al : Glucose intolerance caused by a defect in the entero-insular axis : a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96 : 14843-14847, 1999
 
11) Nauck MA, Heimesaat MM, Orskov C et al : Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 : 301-307, 1993
 
12) Kubota A, Yamada Y, Hayami T et al : Identification of two missense mutations in the GIP receptor gene : a functional study and association analysis with NIDDM : no evidence of association with Japanese NIDDM subjects. Diabetes 45 : 1701-1705, 1996
PubMed
13) Pamir N, Lynn FC, Buchan AM et al : Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 284 : E931-E939, 2003
PubMed
14) Miyawaki K, Yamada Y, Ban N et al : Inhibition of gastric inhibitory polypeptide signaling Prevents obesity. Nat Med 8 : 738-742, 2002
PubMed
15) Yamada Y, Miyawaki K, Tsukiyama K et al : Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55 : S86-S91, 2006
 
16) Yamada C, Yamada Y, Tsukiyama K et al : Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes. Biochem Biophys Res Commun 364 : 175-180, 2007
PubMed
17) Gault VA, McClean PL, Cassidy RS et al : Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50 : 1752-1762, 2007
PubMed
18) Tsukiyama K, Yamada Y, Yamada C et al : Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 20 : 1644-1651, 2006
PubMed
P.44 掲載の参考文献
1) Brubaker PL : The glucagon-like peptides : pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 1070 : 10-26, 2006
PubMed
2) Anini Y, Brubaker PL : Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144 : 3244-3250, 2003
PubMed
3) Theodorakis MJ, Carlson O, Michopoulos S et al : Human duodenal enteroendocrine cells : source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290 : E550-E559, 2006
PubMed
4) Tolhurst G, Reimann F, Gribble FM : Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 587 : 27-32, 2009
PubMed
5) Reimann F, Gribble FM : Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51 : 2757-2763, 2002
PubMed
6) Reimann F, Habib AM, Tolhurst G et al : Glucose sensing in L cells : a primary cell study. Cell Metab 8 : 532-539, 2008
 
7) Cani PD, Holst JJ, Drucker DJ et al : GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol 276 : 18-23, 2007
PubMed
8) Hansen L, Hartmann B, Mineo H et al : Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Rept 118 : 11-18, 2004
 
9) Gribble FM, Williams L, Simpson AK et al : A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52 : 1147-1154, 2003
PubMed
10) Jang HJ, Kokrashvili Z, Theodorakis MJ et al : Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104 : 15069-15074, 2007
PubMed
11) Edfalk S, Steneberg P, Edlund H : Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57 : 2280-2287, 2008
PubMed
12) Hirasawa A, Tsumaya K, Awaji T : Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11 : 90-94, 2005
PubMed
13) Lauffer LM, Iakoubov R, Brubaker PL : GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58 : 1058-1066, 2009
PubMed
14) Katsuma S, Hirasawa A, Tsujimoto G : Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329 : 386-390, 2005
 
15) Reimann F, Williams L, da Silva Xavier G et al : Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47 : 1592-1601, 2004
PubMed
16) Hansen L, Hartmann B, Bisgaard T et al : Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278 : E1010-E1018, 2000
PubMed
17) Holst JJ : The physiology of glucagon-like peptide 1. Physiol Rev 87 : 1409-1439, 2007
PubMed
18) Wang H, Iezzi M, Theander S et al : Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells. Diabetologia 48 : 720-731, 2005
PubMed
19) de Heer J, Rasmussen C, Coy DH et al : Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51 : 2263-2270, 2008
 
20) Baggio LL, Drucker DJ : Biology of incretins : GLP-1 and GIP. Gastroenterology 132 : 2131-2157, 2007
PubMed
21) Friedrichsen BN, Neubauer N, Lee YC : Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 188 : 481-492, 2006
 
22) Glauser DA, Schlegel W : The emerging role of FOXO transcription factors in pancreatic β cells. J Endocrinol 193 : 195-207, 2007
 
23) Briaud I, Lingohr MK, Dickson LM et al : Differential activation mechanisms of Erk-1/2 and p70 (S6K) by glucose in pancreatic β-cells. Diabetes 52 : 974-983, 2003
 
24) Heit JJ, Apelqvist AA, Gu X et al : Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function. Nature 443 : 345-349, 2006
 
25) Song WJ, Schreiber WE, Zhong E et al : Exendin-4 stimulation of cyclin A2 in β-cell proliferation. Diabetes 57 : 2371-2381, 2008
 
26) Jin T, Liu L : The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 22 : 2383-2392, 2008
PubMed
27) Yusta B, Baggio LL, Estall JL et al : GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4 : 391-406, 2006
 
28) Zhou J, Pineyro MA, Wang X et al : Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells : involvement of PDX-1 and HNF3β transcription factors. J Cell Physiol 192 : 304-314, 2002
 
29) Li WC, Horb ME, Tosh D et al : In vitro transdifferentiation of hepatoma cells into functional pancreatic cells. Mech Dev 122 : 835-847, 2005
PubMed
30) Schirra J, Sturm K, Leicht P et al : Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101 : 1421-1430, 1998
PubMed
31) Li Y, Hansotia T, Yusta B et al : Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem 278 : 471-478, 2003
 
32) Talsania T, Anini Y, Siu S et al : Peripheral exendin-4 and peptide YY (3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 : 3748-3756, 2005
PubMed
33) During MJ, Cao L, Zuzga DS et al : Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 : 1173-1179, 2003
PubMed
34) Nakagawa A, Satake H, Nakabayashi H et al : Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110 : 36-43, 2004
 
35) Nakabayashi H, Nishizawa M, Nakagawa A et al : Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271 : E808-E813, 1996
PubMed
36) Meier JJ, Gallwitz B, Salmen S et al : Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 : 2719-2725, 2003
PubMed
37) Meier JJ, Kemmeries G, Holst JJ et al : Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54 : 2212-2218, 2005
PubMed
38) Meier JJ, Nauck MA : Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 21 : 91-117, 2005
PubMed
39) Nikolaidis LA, Elahi D, Hentosz T et al : Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 : 955-961, 2004
PubMed
40) Bose AK, Mocanu MM, Carr RD et al : Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 : 146-151, 2005
PubMed
41) Ban K, Noyan-Ashraf MH, Hoefer J et al : Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 : 2340-2350, 2008
PubMed
42) Nystrom T, Gutniak MK, Zhang Q et al : Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 : E1209-E1215, 2004
PubMed
43) Ryan AS, Egan JM, Habener JF et al : Insulinotropic hormone glucagon-like peptide-1- (7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83 : 2399-2404, 1998
 
44) Vara E, Arias-Diaz J, Garcia C et al : Glucagon-like peptide-1 (7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med 163 : 840-846, 2001
PubMed
45) Gutzwiller JP, Tschopp S, Bock A et al : Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89 : 3055-3061, 2004
 
46) Vilsboll T, Krarup T, Deacon CF et al : Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 : 609-613, 2001
PubMed
47) Koehler JA, Drucker DJ : Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 55 : 1369-1379, 2006
 
P.50 掲載の参考文献
1) Unger RH, Eisentraut AM : Entero-insular axis. Arch Intern Med 123 : 261-266, 1969
PubMed
2) Bishop AE, Polak JM, Green IC et al : The location of VIP in the pancreas of man and rat. Diabetologia 18 : 73-78, 1980
PubMed
3) Ahren B, Lundquist I : Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse. Diabetologia 20 : 54-59, 1981
PubMed
4) Kato I, Suzuki Y, Akabane A et al : Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic β cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J Biol Chem 269 : 21223-21228, 1994
 
5) Miyata A, Arimura A, Dahl RR et al : Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 : 567-574, 1989
PubMed
6) Yada T, Sakurada M, Ishihara H et al : Pituitary adenylate cyclase-activating poly-peptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol 505 : 319-328, 1997
 
7) Portela-Gomes GM, Lukinius A, Ljungberg O et al : PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept 113 : 31-39, 2003
PubMed
8) Vaudry D, Gonzalez BJ, Basille M et al : Pituitary adenylate cyclase-activating poly-peptide and its receptors : from structure to functions. Pharmacol Rev 52 : 269-324, 2000
 
9) Borboni P, Porzio O, Pierucci D et al : Molecular and functional characterization of pituitary adenylate cyclase-activating poly-peptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic β-cells and effects of PACAP-38 on components of the insulin secretory system. Endocrinology 140 : 5530-5537, 1999
 
10) Yada T, Sakurada M, Ihida K et al : Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet β-cells. J Biol Chem 269 : 1290-1293, 1994
 
11) Yamada H, Watanabe M, Yada T : Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic β-cells are mediated by VPAC2 and PAC1 receptors. Regul Pept 123 : 147-153, 2004
 
12) Jamen F, Persson K, Bertrand G et al : PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105 : 1307-1315, 2000
PubMed
13) Asnicar MA, Koster A, Heiman ML et al : Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 143 : 3994-4006, 2002
PubMed
14) Yamamoto K, Hashimoto H, Tomimoto S et al : Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52 : 1155-1162, 2003
 
15) Yanagida K, Yaekura K, Arima T et al : Glucose-insensitivity induced by Ca2+ toxicity in islet β-cells and its prevention by PACAP. Peptides 23 : 135-142, 2002
 
16) Rachdi L, Marie JC, Scharfmann R : Role for VPAC2 receptor-mediated signals in pancreas development. Diabetes 52 : 85-92, 2003
PubMed
17) Nakata M, Shioda S, Oka Y et al : Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3L1 cells. Peptides 20 : 943-948, 1999
PubMed
18) Tsutsumi M, Claus TH, Liang Y et al : A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal : a potential therapy for type 2 diabetes. Diabetes 51 : 1453-1460, 2002
 
19) Pettersson M, Ahren B : Gastrin releasing peptide (GRP) : effects on basal and stimulated insulin and glucagon secretion in the mouse. Peptides 8 : 55-60, 1987
PubMed
20) Karlsson S, Sundler F, Ahren B : Direct cytoplasmic Ca2+ responses to gastrin-releasing peptide in single β cells. Biochem Biophys Res Commun 280 : 610-614, 2001
 
21) Karlsson S, Sundler F, Ahren B : Insulin secretion by gastrin-releasing peptide in mice : ganglionic versus direct islet effect. Am J Physiol 274 : E124-E129, 1998
PubMed
22) Persson K, Pacini G, Sundler F et al : Islet function phenotype in gastrin-releasing peptide receptor gene-deficient mice. Endocrinology 143 : 3717-3726, 2002
PubMed
23) Ahren B, Holst JJ, Efendic S : Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85 : 1043-1048, 2000
PubMed
24) Takiguchi S, Takata Y, Funakoshi A et al : Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 197 : 169-175, 1997
PubMed
25) Weller A, Smith GP, Gibbs J : Endogenous cholecystokinin reduces feeding in young rats. Science 247 : 1589-1591, 1990
PubMed
26) Ahren B, Hughes TE : Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 : 2055-2059, 2005
PubMed

Part 3 DPP - 4の基礎をみる

P.56 掲載の参考文献
1) Lambeir AM, Durinx C, Scharpe S et al : Dipeptidyl-peptidase IV from bench to bedside : an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40 : 209-294, 2003
PubMed
2) Hopsu-Havu VK, Glenner GG : A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 7 : 197-201, 1966
 
3) Hegen M, Kameoka J, Dong RP et al : Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. Adv Exp Med Biol 421 : 109-116, 1997
 
4) Morimoto C, Schlossman SF : The structure and function of CD26 in the T-cell immune response. Immunol Rev 161 : 55-70, 1998
 
5) Hegen M, Mittrucker HW, Hug R et al : Enzymatic activity of CD26 (dipeptidyl peptidase IV) is not rquired for its signalling function in T cells. Immunobiology 189 : 483-493, 1993
PubMed
6) Ogata S, Misumi Y, Ikehara Y : Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem 264 : 3596-3601, 1989
PubMed
7) Misumi Y, Hayashi Y, Arakawa F et al : Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1131 : 333-336, 1992
PubMed
8) Lodja Z : Studies on dipeptidyl (amino) pep-tidase IV (glycyl-proline naphthylamidase). II. Blood vessels. Histochemistry 59 : 153-166, 1979
 
9) Poulsen MD, Hansen GH, Dabelsteen E et al : Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J Histochem Cytochem 41 : 81-88, 1993
 
10) Bernstein HG, Schon E, Ansorge S et al : Immunolocalization of dipeptidyl amino-peptidase (DAP IV) in the developing human brain. Int J Dev Neurosci 5 : 237-242, 1987
 
11) Abbott CA, Baker E, Sutherland GR et al : Genomic organization, exact localization, and tissue expression of the human CD26 (dipep-tidyl peptidase IV) gene. Immunogenetics 40 : 331-338, 1994
 
12) Abbott CA, McCaughan GW, Levy MT et al : Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain. Eur J Biochem 266 : 798-810, 1999
 
13) Weihofen WA, Liu J, Reutter W et al : Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiliphilic interface. J Biol Chem 279 : 43330-43335, 2004
 
14) Mentlein R : Dipeptidyl-peptidase IV (CD26) --role in the inactivation of regulatory peptides. Regul Pept 85 : 9-24, 1999
PubMed
15) Lambeir AM, Diaz Pereira JF, Chacon P et al : A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta 1340 : 215-226, 1997
 
16) Bongers J, Lambros T, Ahmad M et al : Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1122 : 147-153, 1992
PubMed
17) Martin RA, Cleary DL, Guido DM et al : Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta 1164 : 252-260, 1993
PubMed
18) Proost P, Struyf S, Schols D et al : Truncation of macrophage-derived chemokine by CD26/dipeptidyl peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 274 : 3988-3993, 1999
PubMed
19) Chen X : Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8. Adv Exp Med Biol 575 : 27-32, 2006
PubMed
20) Pauly RP, Rosche F, Wermann M et al : Investigation of glucose-dependent insulinotropic polypeptide- (1-42) and glucagon-like peptide-1- (7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 271 : 23222-23229, 1996
PubMed
21) Mentlein R, Dahms P, Grandt D et al : Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49 : 133-144, 1993
PubMed
22) Lambeir AM, Proost P, Durinx C et al : Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 276 : 29839-29845, 2001
PubMed
23) Kikuchi M, Fukuyama K, Epstein WL : Soluble dipeptidyl peptidase IV from terminal differentiated rat epidermal cells : purification and its activity on synthetic and natural peptides. Arch Biochem Biophys 266 : 369-376, 1988
PubMed
24) Lambeir AM, Durinx C, Proost P et al : Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 507 : 327-330, 2001
PubMed
25) Lugari R, Dei Cas A, Ugolotti D et al : Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36 : 111-115, 2004
PubMed
26) Marguet D, Baggio L, Kobayashi T et al : Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97 : 6874-6879, 2000
PubMed
27) Richter B, Bandeira-Echtler E, Bergerhoff K et al : Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev CD006739, 2008
PubMed

Part 4 DPP - 4阻害薬の基礎をみる

P.66 掲載の参考文献
1) Pei Z : From the bench to the bedside : dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel 11 : 512-532, 2008
 
2) Thomas L, Eckhardt M, Langkopf E et al : (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325 : 175-182, 2008
 
3) Croxtall JD, Keam SJ : Vildagliptin : a review of its use in the management of type 2 diabetes mellitus. Drugs 68 : 2387-2409, 2008
PubMed
4) Dhillon S, Weber J : Saxagliptin. Drugs 69 : 2103-2114, 2009
PubMed
5) Gallwitz B : Review of sitagliptin phosphate : a novel treatment for type 2 diabetes. Vasc Health Risk Manag 3 : 203-210, 2007
PubMed
6) Pratley RE : Alogliptin : a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmachother 10 : 503-512, 2009
PubMed
7) Hansotia T, Baggio LL, Delmeire D et al : Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducting the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 : 1326-1335, 2004
 
8) Nauck MA, Homberger E, Siegel EG et al : Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 : 492-498, 1986
 
9) Farilla L, Bulotta A, Hirshberg B et al : Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 : 5149-5158, 2003
PubMed
10) Yamamoto K, Hashimoto H, Tomimoto S et al : Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52 : 1155-1162, 2003
 
11) Ahren B, Hughes TE : Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 : 2055-2059, 2005
PubMed
12) Hamagami K, Sakurai Y, Shintani N et al : Over-expression of pancreatic pituitary adenylate cyclase-activating polypeptide (PACAP) aggrevates cerulein-induced acute pancreatitis in mice. J Pharmacol Sci 110 : 451-458, 2009
 
13) Lamont BJ, Drucker DJ : Differential antidiabetic efficacy of increin agonists versus DPP-4 inhibition in high fat-fed mice. Diabetes 57 : 190-198, 2008
PubMed
14) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
15) Azuma K, Radikova Z, Mancino J et al : Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93 : 459-464, 2008
PubMed
16) Duez H, Smith AC, Xiao C et al : Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology 150 : 56-62, 2009
PubMed
17) Flock G, Baggio LL, Longuet C et al : Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 : 3006-3013, 2007
PubMed
18) Drucker DJ : Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes : preclinical biology and mechanisms of action. Diabetes Care 30 : 1335-1343, 2007
PubMed
P.78 掲載の参考文献
1) Meier JJ, Gallwitz B, Salmen S et al : Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 : 2719-2725, 2003
PubMed
2) Chia CW, Carlson OD, Kim W et al : Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58 : 1342-1349, 2009
PubMed
3) Mentlein R : Dipeptidyl-peptidase 4 (CD26) --role in the inactivation of regulatory peptides. Regul Pept 85 : 9-24, 1999
PubMed
4) Zhu L, Tamvakopoulos C, Xie D et al : The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides : in vivo metabolism of pituitary adenylate cyclase activating Polypeptide- (1-38). J Biol Chem 278 : 22418-22423, 2003
 
5) Hansotia T, Baggio LL, Delmeire D et al : Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 : 1326-1335, 2004
PubMed
6) Nauck MA, El-Ouaghlidi A : The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 : 608-611, 2005
 
7) Holst JJ, Deacon CF : Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48 : 612-615, 2005
PubMed
8) Vilsboll T, Krarup T, Madsbad S et al : Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Rept 114 : 115-121, 2003
 
9) Preitner F, Ibberson M, Franklin I et al : Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113 635-645, 2004
PubMed
10) Moens K, Heimberg H, Flamez D et al : Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45 : 257-261, 1996
PubMed
11) Ding WG, Renstrom E, Rorsman P et al : Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+ -induced secretion in rat α-cells by a protein kinase A-mediated mechanism. Diabetes 46 : 792-800, 1997
 
12) Meier JJ, Gallwitz B, Siepmann N et al : Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46 : 798-801, 2003
PubMed
13) Tornehave D, Kristensen P, Romer J et al : Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56 : 841-851, 2008
PubMed
14) Heller RS, Kieffer TJ, Habener JF : Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 46 : 785-791, 1997
 
15) Dillon JS, Lu M, Bowen S et al : The recombinant rat glucagon-like peptide-1 receptor, expressed in an α-cell line, is coupled to adenylyl cyclase activation and intracellular calcium release. Exp Clin Endocrinol Diabetes 113 : 182-189, 2005
 
16) Ishihara H, Maechler P, Gjinovci A et al : Islet β-cell secretion determines glucagon release from neighbouring α-cells. Nat Cell Biol 5 : 330-335, 2003
 
17) Slucca M, Harmon JS, Oseid EA et al : ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. Diabetes 59 : 128-134, 2010
PubMed
18) Kawamori D, Kurpad AJ, Hu J et al : Insulin signaling in α cells modulates glucagon secretion in vivo. Cell Metab 9 : 350-361, 2009
 
19) Rorsman P, Salehi SA, Abdulkader F et al : KATP -channels and glucose-regulated glucagon secretion. Trends Endocrinol Metab 19 : 277-284, 2008
 
20) Foley JE, Ligueros-Saylan M, He YL et al : Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 40 : 727-730, 2008
PubMed
21) Aschner P, Kipnes MS, Lunceford JK et al : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 : 2632-2637, 2006
PubMed
22) Meier JJ : The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 23 : 433-441, 2009
 
23) Mari A, Ferrannini E : β-cell function assessment from modelling of oral tests : an effective approach. Diabetes Obes Metab 10 (Suppl 4) : S77-S87, 2008
 
24) Xu L, Man CD, Charbonnel B et al : Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on β-cell function in patients with type 2 diabetes : a model-based approach. Diabetes Obes Metab 10 : 1212-1220, 2008
 
25) Mari A, Scherbaum WA, Nilsson PM et al : Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 93 : 103-109, 2008
PubMed
26) Meier JJ, Deacon CF, Schmidt WE et al : Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 50 : 806-813, 2007
PubMed
27) Ahren B, Schweizer A, Dejager S et al : Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94 : 1236-1243, 2009
PubMed
28) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
P.84 掲載の参考文献
1) Verspohl EJ : Novel therapeutics for type 2 diabetes : incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 124 : 113-138, 2009
PubMed
2) Thornberry NA, Gallwitz B : Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23 : 479-486, 2009
PubMed
3) Conarello SL, Li Z, Ronan J et al : Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100 : 6825-6830, 2003
PubMed
4) Sudre B, Broqua P, White RB et al : Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51 : 1461-1469, 2002
PubMed
5) Matveyenko AV, Dry S, Cox HI et al : Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes : interactions with metformin. Diabetes 58 : 1604-1615, 2009
PubMed
6) Mu J, Woods J, Zhou YP et al : Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 : 1695-1704, 2006
 
7) Pospisilik JA, Martin J, Doty T et al : Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 : 741-750, 2003
 
8) Scott R, Loeys T, Davies MJ et al : Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 10 : 959-969, 2008
PubMed
9) Bolli G, Dotta F, Rochotte E et al : Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin : a 24-week, randomized, double-blind study. Diabetes Obes Metab 10 : 82-90, 2008
PubMed
10) Matikainen N, Manttari S, Schweizer A et al : Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49 : 2049-2057, 2006
PubMed
11) Azuma K, Radikova Z, Mancino J et al : Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93 : 459-464, 2008
PubMed
12) Ahren B, Pacini G, Foley JE et al : Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28 : 1936-1940, 2005
 
13) Ahren B, Winzell MS, Wierup N et al : DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 143 : 97-103, 2007
 
14) Ahren B, Hughes TE : Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 : 2055-2059, 2005
PubMed

Part 5 DPP-4阻害薬の臨床データをみる

P.95 掲載の参考文献
1) Herman GA, Stevens C, Van Dyck K et al : Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects : results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78 : 675-688, 2005
PubMed
2) Bergman AJ, Stevens C, Zhou Y et al : Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor : a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 : 55-72, 2006
PubMed
3) Narita H, Nonaka K, Stevens C et al : Multiple dose administration of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in healthy Japanese subjects. Diabetes 55 (Suppl 1) : A127, 2006
 
4) Herman GA, Bergman A, Stevens C et al : Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 : 4612-4619, 2006
PubMed
5) He YL, Sabo R, Campestrini J et al : The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 65 : 338-346, 2008
PubMed
6) He YL, Wang Y, Bullock JM et al : Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47 : 633-641, 2007
PubMed
7) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
8) Ahren B, Landin-Olsson M, Jansson PA et al : Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 : 2078-2084, 2004
PubMed
9) Vincent SH, Reed JR, Bergman AJ et al : Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos 35 : 533-538, 2007
PubMed
10) Bergman AJ, Cote J, Yi B et al : Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30 : 1862-1864, 2007
PubMed
11) Chu XY, Bleasby K, Yabut J et al : Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, oganic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321 : 673-683, 2007
 
12) Migoya EM, Stevens CH, Bergman AJ et al : Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 16 : e165-e170, 2009
PubMed
13) He H, Tran P, Yin H et al : Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 37 : 536-544, 2009
PubMed
14) Thuren T, Byiers S, Mohideen P et al : Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. Diabetologia 50 (Suppl 1) : S1, 2007
 
P.105 掲載の参考文献
1) Nauck MA, Heimesaat MM, Orskov C et al : Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 : 301-307, 1993
 
2) Vilsboll T, Krarup T, Madsbad S et al : Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45 : 1111-1119, 2002
PubMed
3) Mu J, Woods J, Zhou YP et al : Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 : 1695-1704, 2006
 
4) Drucker DJ : Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12 : 87-100, 2003
PubMed
5) Aschner P, Kipnes MS, Lunceford JK et al : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 : 2632-2637, 2006
PubMed
6) Barzilai N, Mahone E, Guo H et al : Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM. ADA 69th poster sessions, 2009 (New Orleans, LA)
 
7) Nonaka K, Tsubouchi H, Okuyama K et al : Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 41 : 232-237, 2009
PubMed
8) Nonaka K, Kakikawa T, Sato A et al : Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79 : 291-298, 2008
PubMed
9) Scott R, Hartley P, Luo E et al : Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI). Diabetes 55 (Suppl 1) : A462, 2006
 
10) Mistry GC, Maes AL, Lasseter KC et al : Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48 : 592-598, 2008
PubMed
11) Lumb AN, Gallen IW : Treatment of HNF1-alpha MODY with the DPP-4 inhibitor sitagliptin. Diabet Med 26 : 189-190, 2009
PubMed
12) Karasik A, Charbonnel B, Liu J et al : Sitagliptin added to ongoing metfbrmin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Diabetes 55 (Suppl 1) : A119, 2006
 
13) Williams-Herman D, Johnson J, Teng R et al : Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes : a 54-week study. Curr Med Res Opin 25 : 569-583, 2009
PubMed
14) Kadowaki T, Tajima N, Odawara M et al : Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM). ADA 68th poster sessions, 2008 (San Francisco, CA)
 
15) Goldstein BJ, Feinglos MN, Lunceford JK et al : Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 : 1979-1987, 2007
PubMed
16) Rosenstock J, Brazg R, Andryuk PJ et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 : 1556-1568, 2006
 
17) Kashiwagi A, Tajima N, Kadowaki T et al : Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM). ADA 68th poster sessions, 2008 (San Francisco, CA)
 
18) Hermansen K, Kipnes M, Luo E et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9 : 733-745, 2007
PubMed
19) Tajima N, Kadowaki T, Odawara M et al : Sitagliptin added to ongoing treatment with Glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM). ADA 68th poster sessions, 2008 (San Francisco, CA)
 
20) Vilsboll T, Rosenstock JM, Yki-Jarvinen H et al : Sitagliptin, a selective DPP-4 inhibitor, improves glycemic control when added to insulin, with or without metformin, in patients with type 2 Diabetes. ADA 69th poster sessions, 2009 (New Orleans, LA)
 
21) Williams-Herman D, Round E, Swern AS et al : Safety and tolerability of sitagliptin in patients with type 2 diabetes : a pooled analysis. BMC Endocr Disord 8 : 14, 2008
PubMed
22) DeFronzo RA, Okerson T, Viswanathan P et al : Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake : a randomized, cross-over study. Curr Med Res Opin 24 : 2943-2952, 2008
PubMed
23) Kao DP, Kohrt HE, Kugler J : Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25 : 1229-1230, 2008
PubMed
24) Ahren B : GLP-1 : effects and side effects, Incretins at Work. 45th EASD symposium, Vienna, Austria, Oct 2, 2009
 
25) Mu J, Petrov A, Eiermann GJ et al : Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623 : 148-154, 2009
 
P.121 掲載の参考文献
1) He YL, Sadler BM, Sabo R et al : The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 46 : 787-802, 2007
PubMed
2) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
3) Kikuchi M, Abe N, Kato M et al : Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83 : 233-240, 2009
PubMed
4) Iwamoto Y, Kashiwagi A, Yamada N et al : Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes (T2DM) : superior efficacy and tolerability with vildagliptin. Diabetes 57 (suppl 1) : A167, 2008
 
5) 菊池方利, 羽田勝計, 古家大祐ほか : 2型糖尿病におけるビルダグリプチンとグリメピリドの併用効果 二重盲検群間比較試験. 糖尿病 52 (suppl 1) : S257, 2009
 
6) Croxtall JD, Keam SJ : Vildagliptin : a review of its use in the management of type 2 diabetes mellitus. Drugs 68 : 2387-2409, 2008
PubMed
7) Dejager S, Razac S, Foley JE et al : Vildagliptin in drug-naive patients with type 2 diabetes : a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39 : 218-223, 2007
PubMed
8) Pi-Sunyer FX, Schweizer A, Mills D et al : Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76 : 132-138, 2007
PubMed
9) Pan C, Yang W, Barona JP et al : Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes : a 24-week, double-blind, randomized trial. Diabet Med 25 : 435-441, 2008
 
10) Rosenstock J, Baron MA, Dejager S et al : Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes : a 24-week, double-blind, randomized trial. Diabetes Care 30 : 217-223, 2007
PubMed
11) Nathan DM, Buse JB, Davidson MB et al : Management of hyperglycemia in type 2 diabetes : A consensus algorithm for the initiation and adjustment of therapy : a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 : 1963-1972, 2006
 
12) Schweizer A, Couturier A, Foley JE et al : Comparison between vildagliptin and metformin to sustain reductions in HbA (1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24 : 955-961, 2007
PubMed
13) Rosenstock J, Fitchet M : Vildagliptin : clinical trials programme in monotherapy and combination therapy for type 2 diabetes. Int J Clin Pract Suppl 159 : 15-23, 2008
PubMed
14) Bosi E, Camisasca RP, Collober C et al : Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 : 890-895, 2007
PubMed
15) Garber AJ, Foley JE, Banerji MA et al : Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10 : 1047-1056, 2008
PubMed
16) Garber AJ, Schweizer A, Baron MA et al : Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy : a randomized, placebo-controlled study. Diabetes Obes Metab 9 : 166-174, 2007
PubMed
17) Fonseca V, Schweizer A, Albrecht D et al : Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 : 1148-1155, 2007
PubMed
18) Bolli G, Dotta F, Rochotte E et al : Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin : a 24-week, randomized, double-blind study. Diabetes Obes Metab 10 : 82-90, 2008
PubMed
19) Ferrannini E, Fonseca V, Zinman B et al : Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11 : 157-166, 2009
PubMed
20) Kothny W, Schweizer A, Dickinson S et al : Hepatic safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. 45th Annual Meeting of European Association for the Study of Diabetes Abstract, 2009
 
21) Ligueros-Saylan M, Schweizer A, Dickinson S et al : Vildagliptin therapy is not associated with an increased risk of pancreatitis. 45th Annual Meeting of European Association for the Study of Diabetes Abstract, 2009
 
22) Foley J, Hoffmann P, Ligueros-Saylan M et al : Lack of vildagliptin effects on the immune system. 45th Annual Meeting of European Association for the Study of Diabetes Abstract, 2009
 

Part 6 糖尿病治療の問題点とインクレチン・DPP - 4への期待を探る

P.130 掲載の参考文献
1) 河盛隆造 : 第45回日本糖尿病学会年次学術集会 会長講演, 糖のながれのシステム生物学. 糖尿病 46 : 101-105, 2003
 
2) 河盛隆造 : ハーゲドーン賞受賞講演, 糖のながれにおける肝・糖取り込み率制御因子の解明. 糖尿病 49 : 771-773, 2006
 
3) Kawamori R, Morishima T, Ikeda M et al : Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 23 : 155-161, 1994
PubMed
4) Scheen AJ : Voglibose for prevention of type 2 diabetes mellitus. Lancet 373 : 1579-1580, 2009
PubMed
5) Kawamori R, Tajima N, Iwamoto Y et al : Voglibose for prevention of type 2 diabetes mellitus : a randomized, double-blind trial in Japanese subjects with impaired glucose tolerance. Lancet 373 : 1607-1614, 2009
PubMed
6) Ogihara T, Fujitani Y, Uchida T et al : Combined expression of transcription factors induces AR42J-B13 cells to differentiate into insulin-producing cells. Endocr J 55 : 691-698, 2008
PubMed
P.136 掲載の参考文献
1) Baggio LL, Drucker DJ : Biology of incretins : GLP-1 and GIP. Gastroenterology 132 : 2131-2157, 2007
PubMed
2) 宮川潤一郎, 美内雅之, 難波光義 : 2. GIP, GLP-1の多彩な作用 2) GLP-1. インクレチン治療-GLP-1受容体作動薬とDPP-4阻害薬による新たな糖尿病治療-, 清野裕監修, 稲垣暢也, 難波光義, 山田祐一郎編, フジメディカル出版, 大阪, 2009, pp26-40
 
3) Nauck MA, Stockmann F, Ebert R et al : Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 : 46-52, 1986
 
4) Villsboll T, Krarup T, Deacon CF et al : Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetes patients. Diabetes 50 : 609-613, 2001
 
5) Toft-Nielsen MB, Damholt MB, Madsbad S et al : Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 : 3717-3723, 2001
PubMed
6) Nauck MA, Heimesaat MM, Orskov C et al : Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 : 301-307, 1993
 
7) Vollmer K, Holst JJ, Baller B et al : Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57 : 678-687, 2008
PubMed
8) Theodorakis MJ, Carlson O, Muller DC et al : Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 27 : 1692-1698, 2004
PubMed
9) Kim W, Egan JM : The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60 : 470-512, 2008
PubMed
10) Xu G, Kaneto H, Laybutt DR et al : Down-regulation of GLP-1 and GIP receptor expression by hyperglycemia : possible contribution to impaired incretin effects in diabetes. Diabetes 56 : 1551-1558, 2007
PubMed
11) Shu L, Matveyenko AV, Kerr-Conte J et al : Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with down-regulation of GIP- and GLP-1 receptors and impaired β-cell function. Hum Mol Genet 18 : 2388-2399, 2009
 

Part 7 DPP - 4阻害薬の臨床的意義と将来展望を探る

P.148 掲載の参考文献
1) 清野裕 : 糖尿病の新しい概念. 最新医学 50 : 639-645, 1995
Medical*Online
2) 小林正, 加来浩平, 河盛隆造ほか : 2型糖尿病患者に対するグリメピリド1日1回投与による臨床効果. 糖尿病 47 : 727-735, 2004
 
3) Rothenberg P, Kalbag J, Smith H et al : Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 level and reduces glucose exposure in human. Diabetes 49 (suppl 1) : A39, 2000
 
4) Deacon CF, Nauck MA, Toft-Nielsen M et al : Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 : 1126-1131, 1995
PubMed
5) Nauck MA, Kleine N, Orskov C et al : Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 : 741-744, 1993
PubMed
6) Donahue RP, Abbott RD, Reed DM et al : Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36 : 689-692, 1987
PubMed
7) Chiasson JL, Josse RG, Gomis R et al : Acarbose treatment and the risk of cardio-vascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 290 : 486-494, 2003
PubMed
8) Hanefeld M, Cagatay M, Petrowitsch T et al : Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J 25 : 10-16, 2004
PubMed
9) International Diabetes Federation : Guideline for Management of Postmeal Glucose, 2007
 
10) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
11) Brazg R, Xu L, Dalla Man C et al : Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9 : 186-193, 2007
 
12) Baggio LL, Drucker DJ : Biology of incretins : GLP-1 and GIP. Gastroenterology 132 : 2131-2157, 2007
PubMed
13) Farilla L, Hui H, Bertolotto C et al : Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 : 4397-4408, 2002
PubMed
14) Farilla L, Bulotta A, Hirshberg B et al : Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 : 5149-5158, 2003
PubMed
15) Scherbaum WA, Schweizer A, Mari A et al : Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10 : 1114-1124, 2008
PubMed
16) 菊池方利, 宇都宮一典, 守屋達美ほか : 2型糖尿病患者に対するビルダグリプチンの長期投与での臨床評価. 新薬と臨牀 59 : 137-154, 2010
Medical*Online
P.153 掲載の参考文献
1) Mu J, Woods J, Zhou YP et al : Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 : 1695-1704, 2006
 
2) Iwamoto Y, Taniguchi T, Nonaka K et al : Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J, 2010, Mar 24 [Epub ahead of print]
 
3) Balas B, Baig MR, Watson C et al : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92 : 1249-1255, 2007
PubMed
4) D'Alessio DA, Denney AM, Hermiller LM et al : Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94 : 81-88, 2009
PubMed
5) 菊池方利, 宇都宮一典, 守屋達美ほか : 2型糖尿病患者に対するビルダグリプチンの長期投与での臨床評価-ビルダグリプチン単独療法またはグリメピリドとの併用療法での52週間安全性試験-. 新薬と臨牀 59 : 137-154, 2010
Medical*Online
6) Kikuchi M, Abe N, Kato M et al : Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83 : 233-240, 2009
PubMed
7) 菊池方利, 大西由希子, 羽田勝計ほか : 2型糖尿病におけるビルダグリプチンとグリメピリドの併用効果-二重盲検群間比較試験-. 糖尿病 52 (S1) : 257, 2009
 
8) Iwamoto Y, Kashiwagi A, Yamada N et al : Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes (T2DM) : Superior efficacy and tolerability with vildagliptin. Diabetes 57 (S1) : A167, 2008
 
9) Weng J, Li Y, Xu W et al : Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes : a multicentre randomised parallel-group trial. Lancet 371 : 1753-1760, 2008
 
P.160 掲載の参考文献
1) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998
 
2) Holman RR, Paul SK, Bethel A et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008
 
3) Holman RR, Paul SK, Bethel A et al : Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 : 1565-1576, 2008
 
4) Drucker DJ, Nauck MA : The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 : 1696-1705, 2006
PubMed
5) Ahren B : Glucagon-like peptide-1 (GLP-1) : a gut hormone of potential interest in the treatment of diabetes. Bioessays 20 : 642-651, 1998
PubMed
6) Mentlein R : Dipeptidyl-peptidase IV (CD26) --role in the inactivation of regulatory peptides. Regul Pept 85 : 9-24, 1999
PubMed
7) Aschner P, Kipnes MS, Lunceford JK et al : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 : 2632-2637, 2006
PubMed
8) Pi-Sunyer FX, Schweizer A, Mills D et al : Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76 : 132-138, 2007
PubMed
9) Ahren B, Simonsson E, Larsson H et al : Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 : 869-875, 2002
 
10) Scott R, Wu M, Sanchez M et al : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61 : 171-180, 2007
PubMed
11) Nonaka K, Kakikawa T, Sato A et al : Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79 : 291-298, 2008
PubMed
12) Raz I, Hanefeld M, Xu L et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 : 2564-2571, 2006
PubMed
13) Kikuchi M, Abe N, Kato M et al : Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83 : 233-240, 2009
PubMed
14) Schweizer A, Couturier A, Foley JE et al : Comparison between vildagliptin and metformin to sustain reductions in HbA (1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24 : 955-961, 2007
PubMed
15) Charbonnel B, Karasik A, Liu J et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metfbrmin alone. Diabetes Care 29 : 2638-2643, 2006
PubMed
16) Goldstein BJ, Feinglos MN, Lunceford JK et al : Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 : 1979-1987, 2007
PubMed
17) Bosi E, Camisasca RP, Collober C et al : Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 : 890-895, 2007
PubMed
18) Ahren B, Gomis R, Standl E et al : Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 : 2874-2880, 2004
PubMed
19) Ferranini E, Fonseca V, Zinman B et al : Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11 : 157-166, 2009
 
20) Nauck MA, Meininger G, Sheng D et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone : a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 : 194-205, 2007
 
21) Rosenstock J, Kim SW, Baron MA et al : Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9 : 175-185, 2007
PubMed
22) Garber AJ, Foley JE, Banerji MA et al : Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10 : 1047-1056, 2008
PubMed
23) Fonseca V, Schweizer A, Albrecht D et al : Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 : 1148-1155, 2007
PubMed
24) Hermansen K, Kipnes M, Luo E et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9 : 733-745, 2007
PubMed
25) Narita T, Katsuura Y, Sato T et al : Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 26 : 187-188, 2009
PubMed
26) Matikainen N, Manttari S, Schweizer A et al : Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49 : 2049-2057, 2006
PubMed
27) Kothny W, Gimpelewicz CR, Byiers S et al : Cardiovascular safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetologia 51 (Suppl 1) : S367, 2008
 
28) Mannucci E, Tesi F, Bardini G et al : Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 17 : 336-342, 2004
PubMed
29) Amori RE, Lau J, Pittas AG : Efficacy and safety of incretin therapy in type 2 diabetes : systematic review and meta-analysis. JAMA 298 : 194-206, 2007
PubMed
P.171 掲載の参考文献
1) Elrick H, Stimmler L, Hlad CJ Jr et al : Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 : 1076-1082, 1964
PubMed
2) Rhodes CJ : Type 2 diabetes-a matter of β-cell life and death? Science 307 : 380-384, 2005
 
3) Butler AE, Janson J, Bonner-Weir S et al : β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52 : 102-110, 2003
 
4) Sakuraba H, Mizukami H, Yagihashi N et al : Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45 : 85-96, 2002
 
5) Ueki K, Okada T, Hu J et al : Total insulin and IGF-I resistance in pancreatic β cells causes overt diabetes. Nat Genet 38 : 583-588, 2006
 
6) Kubota N, Terauchi Y, Tobe K et al : Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus. J Clin Invest 114 : 917-927, 2004
 
7) Hashimoto N, Kido Y, Uchida T et al : Ablation of PDK1 in pancreatic β cells induces diabetes as a result of loss of β cell mass. Nat Genet 38 : 589-593, 2006
 
8) Terauchi Y, Takamoto I, Kubota N et al : Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117 : 246-257, 2007
 
9) Weir GC, Bonner-Weir S : A dominant role for glucose in β cell compensation of insulin resistance. J Clin Invest 117 : 81-83, 2007
 
10) Nakamura A, Terauchi Y, Ohyama S et al : Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 150 : 1147-1154, 2009
 
11) Kahn SE, Haffner SM, Heise MA et al : Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 : 2427-2443, 2006
PubMed
12) Finegood DT, McArthur MD, Kojwang D et al : β-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50 : 1021-1029, 2001
 
13) Ishida H, Takizawa M, Ozawa S et al : Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice : Possible protection of β cells from oxidative stress. Metabolism 53 : 488-494, 2004
 
14) Rhodes CJ : Type 2 diabetes-a matter of β-cell life and death? Science 307 : 380-384, 2005
 
15) Pospisilik JA, Martin J, Doty T et al : Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 : 741-750, 2003
 
16) Duttaroy A, Voelker F, Merriam K et al : The DPP-4 inhibitor vildagliptin increases pancreatic β cell neogenesis and decreases apoptosis. Diabetes 54 (Suppl 1) : A141, 2005
 
17) Mu J, Woods J, Zhou YP et al : Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 : 1695-1704, 2006
 
18) Aschner P, Kipnes MS, Lunceford JK et al : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 : 2632-2637, 2006
PubMed
19) Verspohl EJ : Novel therapeutics for type 2 diabetes : incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 124 : 113-138, 2009
PubMed
20) Zhang CL, Katoh M, Shibasaki T et al : The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325 : 607-610, 2009
PubMed
21) Kodama S, Toyonaga T, Kondo T et al : Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β cell regeneration in STZ-treated mice. Biochem Biophys Res Commun 327 : 1170-1178, 2005
 
22) Zhu M, Breslin MB, Lan MS : Expression of a novel zinc-finger cDNA, IA-1, is associated with rat AR42J cells differentiation into insulin-positive cells. Pancreas 24 : 139-145, 2002
PubMed
23) Zhou J, Pineyro MA, Wang X et al : Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells : involvement of PDX-1 and HNF3β transcription factors. J Cell Physiol 192 : 304-314, 2002
 
24) Matveyenko AV, Dry S, Cox HI et al : Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes : interactions with metformin. Diabetes 58 : 1604-1615, 2009
PubMed
25) Yusta B, Baggio LL, Estall JL et al : GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4 : 391-406, 2006
 
P.180 掲載の参考文献
1) マイケル・ブリス (堀田饒訳) : インスリンの発見, 朝日新聞社, 東京, 1993
 
2) Bradley C : Handbook of Psychology and Diabetes, Harwood Academic Publishers, Amsterdam, 1994
 
3) The DCCT Research Group : Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). Diabetes Care 11 : 725-732, 1988
 
4) 石井均, 山本壽一, 大橋靖雄 : インスリン治療に関するQOL質問表 (ITR-QOL) の開発, 糖尿病 44 : 9-15, 2001
 
5) 石井均, 古家美幸, 飯降直男ほか : インスリン治療に関する夜間QOL質問表 (ITR-QOLN) の開発. 糖尿病 51 : 593-600, 2008
 
6) 石井均, Bradley C, Riazi Aほか : 糖尿病治療満足度質問表 (DTSQ) の日本語翻訳と評価に関する研究. 医学のあゆみ 192 : 809-814, 2000
 
7) 石井均, 周東祐仁, 奥山さくら : The Diabetes Medication Satisfaction Questionnaire (Diab-MedSat) の翻訳と計量心理学的検討. 糖尿病 52 : 527-535, 2009
 
8) Testa MA, Simonson DC : Assessment of quality-of-life outcomes. N Engl J Med 334 : 835-840, 1996
PubMed
9) 石井均, 山本壽一, 大橋靖雄 : インスリン治療に関するQOL質問表 (ITR-QOL) の臨床的知見. 糖尿病 44 : 17-22, 2001
 
10) 石井均, 古家美幸, 飯降直男ほか : インスリン治療に関する夜間QOL質問表 (ITR-QOLN) の臨床知見. 糖尿病 51 : 601-608, 2008
 

書評

最近チェックした商品履歴

Loading...